| Indicators | Browse All

Nasus Pharma Ltd. (NSRX)

Healthcare | Drug Manufacturers - General | Tel Aviv-Yafo, Israel | NYSE American
3.08 USD +0.15 (5.119%) ⇧ (July 13, 2026, 3:37 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:29 a.m. EDT

The immediate outlook is bearish due to a severe disconnect between the current price of $2.93 and the consensus analyst target mean of $19.67, suggesting significant upside potential if the turnaround thesis plays out, yet the short-term technicals remain weak with the stock trading well below its 50-day and 200-day moving averages. However, the long-term investment case is fundamentally broken; the company is generating negative free cash flow, posting negative operating cash flow, and reporting negative returns on assets, indicating a business that is currently destroying value rather than creating it. The absence of any price history over the last several years prevents an assessment of multi-year performance trends, leaving the long-term rating anchored at a low level due to these deteriorating operational fundamentals. Finally, there is no dividend income to consider, as the company has not issued any payouts in the last five years, reflecting its focus on survival and capital raising rather than shareholder returns.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.070562
AutoETS0.073378
AutoARIMA0.076104
AutoTheta0.134611

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 36%
H-stat 1.02
Ljung-Box p 0.000
Jarque-Bera p 0.634
Excess Kurtosis -0.62
Attribute Value
Sector Healthcare
Debt to Equity Ratio 4.263
Market Cap 36,069,292
Website https://www.nasuspharma.com

Info Dump

Attribute Value
52 Week Change -0.64484847
Address1 Yigal Alon 65
All Time High 9.99
All Time Low 1.98
Ask 0.0
Ask Size 100
Average Daily Volume10 Day 17,770
Average Daily Volume3 Month 69,780
Average Volume 69,780
Average Volume10Days 17,770
Bid 0.0
Bid Size 200
Book Value 0.307
City Tel Aviv-Yafo
Compensation As Of Epoch Date 1,767,139,200
Country Israel
Crypto Tradeable 0
Currency USD
Current Price 3.08
Current Ratio 2.245
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 3.178
Day Low 3.03
Debt To Equity 4.263
Display Name Nasus Pharma
Ebitda Margins 0.0
Enterprise Value 31,901,288
Eps Trailing Twelve Months -0.72
Esg Populated 0
Exchange ASE
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.07078
Fifty Day Average Change 0.009219885
Fifty Day Average Change Percent 0.0030024569
Fifty Two Week Change Percent -64.48485
Fifty Two Week High 9.99
Fifty Two Week High Change -6.91
Fifty Two Week High Change Percent -0.6916917
Fifty Two Week Low 1.98
Fifty Two Week Low Change 1.0999999
Fifty Two Week Low Change Percent 0.5555555
Fifty Two Week Range 1.98 - 9.99
Financial Currency USD
First Trade Date Milliseconds 1,755,091,800,000
Float Shares 4,856,121
Free Cashflow -3,037,000
Full Exchange Name NYSE American
Full Time Employees 7
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.49165002
Held Percent Institutions 0.18566
Implied Shares Outstanding 11,710,809
Industry Drug Manufacturers - General
Industry Disp Drug Manufacturers - General
Industry Key drug-manufacturers-general
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Long Name Nasus Pharma Ltd.
Market us_market
Market Cap 36,069,292
Market State PRE
Max Age 86,400
Message Board Id finmb_714524293
Most Recent Quarter 1,767,139,200
Net Income To Common -5,805,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 36,069,288
Number Of Analyst Opinions 3
Open 3.01
Operating Cashflow -4,918,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 972 3 573 6632
Previous Close 2.93
Price Hint 4
Price To Book 10.032573
Profit Margins 0.0
Quick Ratio 1.982
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.15
Regular Market Change Percent 5.11945
Regular Market Day High 3.178
Regular Market Day Low 3.03
Regular Market Day Range 3.03 - 3.178
Regular Market Open 3.01
Regular Market Previous Close 2.93
Regular Market Price 3.08
Regular Market Time 1,783,971,452
Regular Market Volume 15,600
Return On Assets -1.07149
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 11,710,808
Shares Percent Shares Out 0.0147
Shares Short 172,140
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 172,484
Short Name Nasus Pharma Ltd.
Short Percent Of Float 0.026300002
Short Ratio 5.01
Source Interval 15
Symbol NSRX
Target High Price 22.0
Target Low Price 18.0
Target Mean Price 19.66667
Target Median Price 19.0
Total Cash 4,286,000
Total Cash Per Share 0.366
Total Debt 118,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.72
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.17073
Two Hundred Day Average Change -2.0907302
Two Hundred Day Average Change Percent -0.40433946
Type Disp Equity
Volume 15,600
Website https://www.nasuspharma.com
Zip 6,744,317